BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11156221)

  • 1. Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.
    O'Dwyer PJ; Szarka C; Brennan JM; Laub PB; Gallo JM
    Clin Cancer Res; 2000 Dec; 6(12):4692-6. PubMed ID: 11156221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells.
    O'Dwyer PJ; Clayton M; Halbherr T; Myers CB; Yao Ks
    Clin Cancer Res; 1997 May; 3(5):783-91. PubMed ID: 9815750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
    Gupta E; Olopade OI; Ratain MJ; Mick R; Baker TM; Berezin FK; Benson AB; Dolan ME
    Clin Cancer Res; 1995 Oct; 1(10):1133-8. PubMed ID: 9815904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours.
    Bae SK; Lee SJ; Kim JW; Kim YH; Kim SG; Lee MG
    Biopharm Drug Dispos; 2005 Mar; 26(2):77-83. PubMed ID: 15617135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
    Benson AB; Olopade OI; Ratain MJ; Rademaker A; Mobarhan S; Stucky-Marshall L; French S; Dolan ME
    Clin Cancer Res; 2000 Oct; 6(10):3870-7. PubMed ID: 11051232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies.
    Dimitrov NV; Leece CM; Tompkins ER; Seymour E; Bennink M; Gardiner J; Crowell J; Hawk E; Nashawaty M; Bennett JL
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):201-7. PubMed ID: 11303588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
    Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
    Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats.
    Bae SK; Kim EJ; Chung SJ; Kim SG; Lee MG
    J Pharm Pharmacol; 2003 Sep; 55(9):1241-9. PubMed ID: 14604467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.
    Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y
    Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic dosing of oltipraz in people at increased risk for colorectal cancer.
    Szarka CE; Yao KS; Pfeiffer GR; Balshem AM; Litwin S; Frucht H; Goosenberg EB; Engstrom PF; Clapper ML; O'Dwyer PJ
    Cancer Detect Prev; 2001; 25(4):352-61. PubMed ID: 11531012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
    Kim SG; Kim YM; Choi YH; Lee MG; Choi JY; Han JY; Cho SH; Jang JW; Um SH; Chon CY; Lee DH; Jang JJ; Yu ES; Lee YS
    Clin Pharmacol Ther; 2010 Sep; 88(3):360-8. PubMed ID: 20664537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
    Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated oral administration modulates the pharmacokinetic behavior of the chemopreventive agent phenethyl isothiocyanate in rats.
    Konsue N; Kirkpatrick J; Kuhnert N; King LJ; Ioannides C
    Mol Nutr Food Res; 2010 Mar; 54(3):426-32. PubMed ID: 19866468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane.
    Reed GA; Arneson DW; Putnam WC; Smith HJ; Gray JC; Sullivan DK; Mayo MS; Crowell JA; Hurwitz A
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2477-81. PubMed ID: 17164373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice.
    Anderton MJ; Manson MM; Verschoyle R; Gescher A; Steward WP; Williams ML; Mager DE
    Drug Metab Dispos; 2004 Jun; 32(6):632-8. PubMed ID: 15155555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
    Zou JJ; Bian XJ; Ding L; Zhu YB; Fan HW; Xiao DW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):151-7. PubMed ID: 18069077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.